| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS46000247 | BKPyv | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS46000268 | BKPyv | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30003768 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30013351 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30008906 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30003769 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30016333 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30016334 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30008907 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30000694 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | NR3C1 |
|---|---|
| DrugBank ID | DB00741 |
| Drug Name | Hydrocortisone |
| Target ID | BE0000794 |
| UniProt ID | P04150 |
| Regulation Type | agonist |
| PubMed IDs | 16891588; 16895953; 16980198; 17038445; 17086345; 15634032 |
| Citations | Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21.@@Rautanen A, Eriksson JG, Kere J, Andersson S, Osmond C, Tienari P, Sairanen H, Barker DJ, Phillips DI, Forsen T, Kajantie E: Associations of body size at birth with late-life cortisol concentrations and glucose tolerance are modified by haplotypes of the glucocorticoid receptor gene. J Clin Endocrinol Metab. 2006 Nov;91(11):4544-51. Epub 2006 Aug 8.@@Hammer F, Stewart PM: Cortisol metabolism in hypertension. Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):337-53.@@Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12.@@Sher L: Combined dexamethasone suppression-corticotropin-releasing hormone stimulation test in studies of depression, alcoholism, and suicidal behavior. ScientificWorldJournal. 2006 Oct 31;6:1398-404.@@Czock D, Keller F, Rasche FM, Haussler U: Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98. doi: 10.2165/00003088-200544010-00003. |
| Groups | Approved; Vet_approved |
| Direct Classification | 21-hydroxysteroids |
| SMILES | [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C |
| Pathways | Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency; Apparent Mineralocorticoid Excess Syndrome; Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH; 3-beta-Hydroxysteroid Dehydrogenase Deficiency; Corticosterone Methyl Oxidase I Deficiency (CMO I); Corticotropin Activation of Cortisol Production; 11-beta-Hydroxylase Deficiency (CYP11B1); Steroidogenesis; Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency; 17-alpha-Hydroxylase Deficiency (CYP17); Corticosterone Methyl Oxidase II Deficiency (CMO II); 21-Hydroxylase Deficiency (CYP21) |
| PharmGKB | PA449905 |
| ChEMBL | CHEMBL389621 |
